Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIXR: CD8 PET Imaging as a Marker of Immune Response to SBRT
NCT05371132Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Jun 2022
- Primary completion
- Oct 2027
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zirconium-89 crefmirlimab berdoxam in malignant solid neoplasm and lymphoma, sponsored by City of Hope. Primary endpoint: Change in CD8 positron emission tomography maximum standardized uptake value. Started Jun 2022; status: recruiting.
02
Drugs
zirconium-89 crefmirlimab berdoxam
03
Conditions
malignant solid neoplasmlymphoma
Beyond the preview
Go deeper on NCT05371132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05371132.